Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~* Chronic hepatitis C viral infection~* Plasma HCV RNA level lower limit ≥ 10,000 IU/ml assessed by quantitative polymerase chain reaction (qPCR) or equivalent at screening (no upper limit)~* HCV genotype 2 or 3~* No previous treatment for hepatitis C infection~Exclusion criteria:~* Evidence of cirrhosis at the time of screening~* Evidence of hepatocellular carcinoma at the time of screening~* Any other cause of relevant liver disease other than HCV~* Alanine aminotransferase (ALT) ≥ 10 times upper limit of normal (ULN)~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ALV 1000 mg (Type: EXPERIMENTAL): Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.
- ALV 600 mg+RBV (Type: EXPERIMENTAL): Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.
- ALV 800 mg+RBV (Type: EXPERIMENTAL): Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
- ALV 600 mg+PEG (Type: EXPERIMENTAL): Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.
- PEG+RBV (Type: ACTIVE_COMPARATOR): Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).